Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

12 API Suppliers, 8 USDMF, 2 EU WC, 5 NDC API, 2 Listed Suppliers, $ API Reference Price

12 API Suppliers
8 USDMF
2 EU WC
5 NDC API
2 Listed Suppliers
$ API Reference Price

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers, 5 FDA Orange Book

5 FDF Dossiers
5 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 174MG, TABLET, EXTENDED RELEASE;ORAL - 348MG, TABLET, EXTENDED RELEASE;ORAL - 522MG

drugProductComposition
TABLET, EXTENDED RELEASE;ORAL - 174MG
TABLET, EXTENDED RELEASE;ORAL - 348MG
TABLET, EXTENDED RELEASE;ORAL - 522MG

RELATED EXCIPIENT COMPANIES

2 Seqens, 1 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 3 Actylis, 1 Alcedo Pharmachem, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 23 BASF, 9 Corel Pharma Chem, 1 Finar, 6 Gangwal Chemicals, 2 Ideal Cures Pvt Ltd, 5 Kerry, 1 Kima Chemical, 2 Microlex e.U, 2 Nomisma Healthcare, 3 Novo Excipients, 2 Pharmatrans-Sanaq, 1 Pluviaendo, 1 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

20 Coating Systems & Additives, 16 Controlled & Modified Release, 15 Disintegrants & Superdisintegrants, 13 Fillers, Diluents & Binders, 12 Granulation, 12 Solubilizers, 11 Direct Compression, 8 Topical, 7 Thickeners and Stabilizers, 5 Parenteral, 4 Chewable & Orodispersible Aids, 4 Film Formers & Plasticizers, 3 Co-Processed Excipients, 3 Taste Masking, 1 API Stability Enhancers

excipientsByApplications
20 Coating Systems & Additives
16 Controlled & Modified Release
15 Disintegrants & Superdisintegrants
13 Fillers, Diluents & Binders
12 Granulation
12 Solubilizers
11 Direct Compression
8 Topical
7 Thickeners and Stabilizers
5 Parenteral
4 Chewable & Orodispersible Aids
4 Film Formers & Plasticizers
3 Co-Processed Excipients
3 Taste Masking
1 API Stability Enhancers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 2 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
2 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 Finished Drug Prices, 6 Annual Reports

globalSalesInformation
3 Finished Drug Prices
6 Annual Reports

PATENTS & EXCLUSIVITIES

24 US Patents

patents
24 US Patents

REF. STANDARDS & IMPURITIES

1 USP , 1 Others

otherSolutions
1 USP
1 Others

LGM Bupropion Hydrobromide

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 191

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

417

Finished Drug Prices

75 RELATED EXCIPIENT COMPANIES

134EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 905818-69-1, Aplenzin, Bupropion hbr, Bupropion hydrobromide [usan], Bupropion (hydrobromide), 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one hydrobromide

Molecular Formula

C₁₃H₁₉BrClNO

Molecular Weight

320.65 g/mol

InChI Key

WSTCENNATOVXKQ-UHFFFAOYSA-N

FDA UNII

E70G3G5863

Bupropion Hydrobromide is the hydrobromide salt of an aminoketone with antidepressant activity. The molecular mechanism of the antidepressant effect of bupropion is unknown. This agent does not inhibit monoamine oxidase and, compared to classical tricyclic antidepressants, is a weak blocker of the neuronal uptake of serotonin and norepinephrine. Buproprion also weakly inhibits the neuronal re-uptake of dopamine.

1 2D Structure

Bupropion Hydrobromide

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;hydrobromide

2.1.2 InChI

InChI=1S/C13H18ClNO.BrH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

2.1.3 InChI Key

WSTCENNATOVXKQ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.Br

2.2 Other Identifiers

2.2.1 UNII

E70G3G5863

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 905818-69-1

2. Aplenzin

3. Bupropion Hbr

4. Bupropion Hydrobromide [usan]

5. Bupropion (hydrobromide)

6. 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one Hydrobromide

7. Bvf-033

8. E70g3g5863

9. Bupropion Hydrobromide (usan)

10. Aplenzin Er

11. Unii-e70g3g5863

12. Aplenzin (tn)

13. Schembl636116

14. Chembl1201735

15. Dtxsid20920317

16. Bupropion Hydrobromide [mi]

17. 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one,hydrobromide

18. 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;hydrobromide

19. Bupropion Hydrobromide [vandf]

20. Akos015917698

21. Bupropion Hydrobromide [mart.]

22. Bupropion Hydrobromide [usp-rs]

23. Bupropion Hydrobromide [who-dd]

24. Bupropion Hydrobromide [orange Book]

25. D07938

26. Q27276951

27. (2rs)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)propan-1-one Hbr

28. (2rs)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)propan-1-one Hydrobromide

29. 1-propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, Hbr (1:1)

30. 1-propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, Hydrobromide (1:1)

31. 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one--hydrogen Bromide (1/1)

2.4 Create Date

2007-01-10

3 Chemical and Physical Properties

Molecular Formula	C₁₃H₁₉BrClNO
Molecular Weight	320.65 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	4
Exact Mass	319.03385 g/mol
Monoisotopic Mass	319.03385 g/mol
Topological Polar Surface Area	29.1 Å²
Heavy Atom Count	17
Formal Charge	0
Complexity	247
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 4
Drug Name	Aplenzin
Active Ingredient	Bupropion hydrobromide
Dosage Form	Tablet, extended release
Route	Oral
Strength	348mg; 522mg; 174mg
Market Status	Prescription
Company	Valeant Bermuda

2 of 4
Drug Name	Bupropion hydrobromide
PubMed Health	Bupropion (By mouth)
Drug Classes	Antidepressant, Smoking Cessation Agent
Active Ingredient	Bupropion hydrobromide
Dosage Form	Tablet, extended release
Route	oral
Strength	522mg; 174mg
Market Status	Tentative Approval
Company	Watson Labs

3 of 4
Drug Name	Aplenzin
Active Ingredient	Bupropion hydrobromide
Dosage Form	Tablet, extended release
Route	Oral
Strength	348mg; 522mg; 174mg
Market Status	Prescription
Company	Valeant Bermuda

4 of 4
Drug Name	Bupropion hydrobromide
PubMed Health	Bupropion (By mouth)
Drug Classes	Antidepressant, Smoking Cessation Agent
Active Ingredient	Bupropion hydrobromide
Dosage Form	Tablet, extended release
Route	oral
Strength	522mg; 174mg
Market Status	Tentative Approval
Company	Watson Labs

5 Pharmacology and Biochemistry

5.1 FDA Pharmacological Classification

5.1.1 Pharmacological Classes

Dopamine Uptake Inhibitors [MoA]; Increased Dopamine Activity [PE]; Increased Norepinephrine Activity [PE]; Norepinephrine Uptake Inhibitors [MoA]; Aminoketone [EPC]

API SUPPLIERS